Table 1.
Clinical applications of pluripotent stem cell-derived CMs as a therapy.
| Trial (year and number) | Phase | Cell therapy | Administration route | Disease | Main findings | Ref. |
|---|---|---|---|---|---|---|
| ESCORT (2018, NCT02057900) | 1 | Transplantation of human embryonic stem cell-derived CD15+ Isl-1+ progenitors | Epicardially delivered during surgical coronary revascularization | Severe heart failure | Sustained contractility, no arrhythmia, tumor formation, nor immunoreaction | 15 |
| BioVAT-HF (2020, NCT04396899) | 2 | iPSC-derived engineered human myocardium | Left-lateral mini-thoracotomy or other interventions | Ventricular assist tissue in terminal heart failure | N.A. | - |
| HEAL-CHF (2021, NCT03763136) | 2 | Allogeneic human pluripotent stem cell-derived CM | Epicardially injected during coronary artery bypass grafting | Severe chronic heart failure | N.A. | - |
| Treating congestive heart failure patients with human iPSC-derived CM through catheter-based endocardial injection (2021, NCT04982081) | 1 | Human iPSC-CM | Transcatheter endocardial injection system | Congestive heart failure | N.A. | - |
| HECTOR (2021, NCT05068674) | 1 | Human embryonic stem cell-derived CM | Transcatheter endocardial injection | Chronic ischemic left ventricular dysfunction | N.A. | - |
| LAPiS (2021, NCT04945018) | 1/2 | Human iPSC-CM spheroids | N.A. | Severe heart failure secondary to ischaemic heart disease | N.A. | - |
| Clinical trial of human (allogeneic) iPSC-derived CM sheet for ischemic cardiomyopathy (2021, NCT04696328) |
1 | iPSC-CM sheet | Transplantation | Ischemic cardiomyopathy | N.A. | - |